Financial terms of the acquisition were not disclosed. The deal will bring e-novex's proprietary Electronic Data Capture (EDC) technology to genae, which can be adopted by pharma, biotech and medical device clients, as well as other CROs, Academic Research Organizations (ARO) and individual researchers.
The portfolio is comprised of e-capture.net for approval studies and edc2go, which allows for the faster building of an electronic Case Report Form (eCRF) in a matter of hours rather than weeks or months. The company’s lab tracker platform also facilitates the management and tracking of image logistics and enables secure transfer of large image data sets.
Bart Segars, CEO of genae, told Outsourcing-Pharma.com: “The technology increases our electronic solutions offering and our eHealth efficiencies in data management and risk based monitoring. We are now able to offer proprietary Electronic Data Capture solutions that are fully integrated with our other services.”
The entire e-novex staff of 12 will be integrated in genae's e-Solutions business unit that already includes data management and statistics efficiencies. There will be no disruptions of e-novex' services during the integration which will take place over the next three months, the companies said.
And the acquisition might be the first of a couple of moves in the area. Segars told us: “genae will continue to invest in IT and technology in the future, including additional acquisitions in that area.”
Most recently, genae has opened a series of offices around the globe, from New York to London to Dubai. The company previously expanded its European reach into Switzerland two years ago.